Kornimate/medical-research-clean huggingface dataset:
metabolic and hemodynamic effects of the inhibitors of type 2 sodium glucose co-transporters (isglt2) in diabetic patients with heart failure

Conditions: Heart Failure

Summary: inhibitors of the type 2 sodium-glucose co-transporter (isglt2) may improve the metabolic and hemodynamic profile in patients with dm2 and heart failure.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * hba1c\> 6.5% * estimated gf\> 45 ml / min * bmi: ≥25 kg / m2 * stable pharmacological treatment of heart failure in the last 3 months exclusion criteria: * diabetes type 1 or type lada (presence of antibodies against gad and/or ia-2 positive) * dm2 with c-peptide \<1 ng / ml * gef \<45 ml / min * recurrent urinary tract infections

Keywords: heart failure diabetes isglt2
resilience for older workers with oa through exercise

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: exercise is effective at reducing pain while improving physical function. however we do not know if exercise can boost resilience in the workplace, to allow people with osteoarthritis to work as long as they desire. previous research shows that exercise holds the most promise for helping people enjoy their work because it reduces sick time, reduces pain, and improves productivity. however, little work has examined the effect of exercise for people with arthritis in the workplace. the purpose of the study is to investigate whether exercise improves resilience in the workplace, mobility, fitness, strength, and pain in comparison to no exercise in those with knee and/or hip osteoarthritis.

the canadian workforce is aging. the most prevalent age group is 50-54 years and most of these canadians will aim to continue working over the next 10 years. however, the impact of arthritis on aging canadians compromises their ability to continue working. by 2031, over 2 million canadians aged 45 to 64 years will have arthritis. we aim to boost the ability of older adults with the most common arthritis, osteoarthritis (oa), to engage in the workforce for as long as they desire. identifying strategies to promote productivity among older workers with knee and hip oa will be of great public health significance in the coming decades. however, we face two challenges. first, obesity among sedentary workers is a risk for worsening knee and hip oa. second, large occupational loads on the knee and hip worsen oa. exercise has the most promise in addressing these challenges because it reduces pain and sick time, and improves mental health. thus, there is a call for studies examining exercise for the aging worker with knee and hip oa. the purpose of this study is to examine the impact of an oa-specific leg strengthening exercise program, delivered within the workplace, on mobility, pain, physical capacity, and resilience among older workers with knee or hip oa.

Eligibility criteria:
inclusion criteria: * 45 years of age or older * mcmaster employee * sedentary job (stand or walk for \<1/3 of work day) * able to safely climb two flights of stairs * hip pain * hip pain during internal rotation and hip flexion * knee pain * less than 30 minutes of morning stiffness in the knee * crepitus in the knee with active range of motion * bony enlargement around the knee * bony tenderness to palpation at the knee * no warmth around the knee exclusion criteria: * any other forms of arthritis * osteoporosis-related fracture * history of patellofemoral symptoms * active non-arthritic hip or knee disease * hip or knee surgery * use of cane or walking aid * unstable heart condition * neurological conditions * hip, knee or ankle injuries in past 3 months * physician-advised restriction to physical activity * any injuries that would prohibit participation in exercise * ipsilateral ankle conditions * currently receiving cancer treatment * currently pregnant

Keywords: exercise resilience
the role of expectations in the pharmacological treatment of depression - an experimental investigation

Conditions: Major Depressive Episode

Summary: the study aimes at identifying whether positive expectations have an impact on the way depressive participants experience emotions in the form of sadness.


Eligibility criteria:
inclusion criteria: * major depression (mild to moderate) * fluent in german language exclusion criteria: * bipolar disorder, psychotic disorder, substance dependence * cardiovascular disease, severe kidney or liver disease, epilepsy * change of psychotropic medication intake within the last four weeks * allergic to capsaicin * allergic to sesame oil * students in medicine, pharmacy, or psychology in their third year or older * completed studies in medicine, pharmacy or psychology
behavioral intervention for hiv and hcv-uninfected injection drug users

Conditions: HIV Infections; Hepatitis C

Summary: the purpose of this study is to test whether a six-session behavioral intervention for hiv and hcv seronegative injection drug users is effective in reducing sexual and injection risk behaviors that could lead to primary hiv and hcv infection.

cidus iii/duit is a five-city (baltimore, chicago, los angeles, new york, and seattle) randomized controlled trial to develop and evaluate the efficacy of a six-session behavioral intervention for hiv and hcv uninfected injection drug users between the ages of 15 and 30 years. the primary goals of the intervention are to: 1. decrease the shared use of syringes and other injection paraphernalia, 2. decrease sexual risk behaviors associated with hiv and hcv infection, and 3. decrease the incidence of hepatitis c virus (hcv) infection. the intervention arm consists of six small-group training and skills-building sessions to teach and reinforce peer education activities around decreasing sex and injection risk behaviors for hiv and hcv infection. in the fifth session, participants practice peer education around sex or injection risk behaviors within their community. the control arm consists of six video and discussion sessions to control for attention. prior to study enrollment, all participants in both arms receive hiv and hcv testing with client-centered pre- and post-test counseling to also control for the demand for risk reduction information. behavioral assessments (by audio computer assisted self interviewing) and blood draws (for serologic testing) occur at baseline, 3 and 6 month follow-up. 3285 participants completed the baseline visit, of whom 1564 tested hiv and hcv seronegative and returned for test results making them eligible to enroll in the intervention trial. of the eligible participants, 854 were randomized into the trial. 606 and 591 returned for 3 and 6 month follow-up assessments, respectively, and 712 participants completed at least one follow-up visit.

Eligibility criteria:
inclusion criteria: * age 15-30 years old * self-reported illicit drug injection within the past 6 months * live in the geographic region under study and plan to stay for \>12 months * willing to provide a blood sample for serologic testing * willing to provide basic contact information for follow-up * able to communicate in english * had not participated in the pilot study or previously enrolled in the trial * not concurrently participating in other hiv or hcv intervention trials * tested hiv and hcv seronegative at baseline exclusion criteria: -

Keywords: iv drug users hiv hepatitis c virus hiv seronegativity
evaluation of the effectiveness of dry needling treatment in patients diagnosed with greater trochanteric pain syndrome

Conditions: Greater Trochanteric Pain Syndrome

Summary: greater trochanteric pain syndrome (gtps) is characterized by lateral hip pain, pain radiating to the lateral leg, tenderness and rotation around the greater trochanter, and pain with specific activities such as abduction or adduction. gtps is primarily diagnosed clinically. conservative treatment for gtps includes activity modification, physiotherapy, nonsteroidal anti-inflammatory drugs, local corticosteroids, and platelet-rich plasma injections. particularly, regional muscle sensitivity, such as in the gluteus maximus, is prominent. in recent years, dry needling therapy, which has gained popularity and increased research attention, has become an alternative treatment option, especially if the underlying cause is myofascial pain syndrome or deeper issues like piriformis syndrome. the provided text discusses dry needling as a treatment for various neuromusculoskeletal pain conditions, emphasizing its use as a minimally invasive procedure that involves applying filiform needles to the relevant muscle tissue without the administration of pharmacological drugs. the literature suggests that dry needling therapy has the ability to induce biochemical, biomechanical, endocrinological, and neurovascular changes associated with the reduction of pain and disability in individuals. however, the optimal treatment dosage has not yet been determined, and there is inconsistency in the literature regarding the number of needles to be inserted and the duration of needle retention. studies evaluating the effectiveness of dry needling are often designed to compare or add it to other injection therapies. additionally, there is a limited number of studies conducted with real-time imaging. in the planned study, the use of ultrasound-guided dry needling aims to provide a sham application opportunity, where the patient is blinded to the nature of the procedure, allowing for a meaningful investigation of efficacy. this aspect of the study is expected to contribute significantly to the literature.


Eligibility criteria:
inclusion criteria: age between 18 and 80 years old. ability to read and write. clinically diagnosed with greater trochanteric pain syndrome. pain visual analog scale (vas) score of 6 or higher. exclusion criteria: history of previous lumbar and hip surgery. lesions, atrophy, or scars in the skin around the hip area. received physiotherapy for the hip, lumbar, or lower extremities in the last 6 months. underwent an interventional procedure for the hip or lumbar region for the same reason in the last 3 months. used steroids in the last 1 month. special conditions such as epilepsy, pregnancy, injection phobia, etc. inability to comply with the restriction on the use of both steroid and non-steroidal anti-inflammatory drugs during the treatment period. subcutaneous fat tissue thickness in the hip area being 5 cm or more.
to evaluate efficacy and long-term safety of ozanimod in japanese subjects with moderately to severely active ulcerative colitis

Conditions: Colitis, Ulcerative

Summary: japanese patients with moderate or severe active ulcerative colitis as a subject when ozanimod 0.46 mg or 0.92 mg is orally administered is evaluated about dose response, efficacy and safety with placebo as a control.

following the up to 5-week screening period, eligible subjects will be randomized to enter the 12 weeks placebo-controlled induction period (ip). subjects who are responders at week 12 will continue on their assigned treatment in the 40-week maintenance period (mp). non responders at week 12 have the option to enter the open-label extension (ole). subjects who complete the mp will be given the option to participate in the ole. subjects that enter the mp and experience disease relapse will also have the option to enter the ole. the ole will continue until marketing launch (about 4 years of ozanimod for ulcerative colitis (uc), or until the sponsor discontinues the development program.

Eligibility criteria:
inclusion criteria: main inclusion criteria for induction and maintenance periods 1. subject is a japanese male or female subjects aged 18 to 75 years at the time of signing the informed consent form (icf) at screening. 2. subject has had ulcerative colitis (uc) diagnosed at least 3 months prior to first investigational product administration. the diagnosis should be confirmed by clinical and endoscopic evidence and corroborated by a histopathology report. 3. subject has evidence of uc extending ≥ 15 cm from the anal verge as determined by baseline endoscopy (flexible sigmoidoscopy or colonoscopy). 4. subject has active uc defined as mayo score of 6 to 12 inclusive, with endoscopic subscore of ≥ 2, a rectal bleeding score of ≥ 1, and a stool frequency score ≥ 1. main inclusion criteria for open-label extension period subjects must satisfy the following criteria to be enrolled in the study: 1. must have completed the week 12 visit and is non-responder at week 12 2. who completes the ip and enters the mp, completes participation through the last study treatment visit at week 52 with maintaining clinical response, or experiences disease relapse during the mp exclusion criteria: main exclusion criteria 1. subject has severe extensive colitis 2. subject has diagnosis of crohn's disease or indeterminate colitis or the presence or history of a fistula consistent with crohn's disease or microscopic colitis or radiation colitis or ischemic colitis. 3. subject has positive stool examination for pathogens (ova and parasites, bacteria) or positive test for toxin producing clostridium difficile (c. difficile) at screening.4. subject is pregnant or breastfeeding 5. subject has clinically relevant cardiovascular conditions

Keywords: ulcerative colitis ozanimod colitis ulcerative
myofunctional therapy twin block

Conditions: Malocclusion, Angle Class II

Summary: there are situations where orthodontic treatment cannot provide long-term benefits. the proposed orthotropic theory proposes that environmental factors cause malocclusion and genes decide its pattern. the primary aim of this project is to increase the success, aesthetics and permanence of the treatment result by providing the best facial change of the pediatric patients in the mp3cap period, and that myofunctional exercises can be used in addition to orthodontic treatments during the treatment process of the patients.

many studies in recent years have emphasized the importance of the environmental factor as well as the hereditary causes of malocclusion. in particular, the activity and posture of the oral soft tissues have begun to be mentioned more. in the presence of bad habits, there are cases where orthodontic treatment alone is not sufficient and must be combined with myofunctional treatments. there are also many physicians who emphasize the importance of positioning the tongue in contact with the palate during swallowing and resting. it is known that habits during growth and development cause malocclusions that may occur in the future. it may be possible to acquire some myofunctional exercises as a habit during the growth and development period as a prophylactic solution against malocclusions. in addition to twin block treatment, myofunctional exercises will be given to class ii pediatric patients in the mp3cap period, and the effect of exercises on oral soft and hard tissues will be compared at the end of the treatment. the effects of tongue and lip movements on facial development as well as on the treatment process will be examined. perhaps in the future, everyone can recommend doing myofunctional exercises in addition to tooth brushing.

Eligibility criteria:
inclusion criteria: 1. having a skeletal class ii relationship (anb \> 4°), 2. skeletal class ii relationship due to mandibular retrognathia (snb \< 78°), 3. overjet is more than 5 mm, 4. normal growth pattern sn-gogn (32° ± 6°), 5. minimum crowding of the dental arch is 4 mm or less, 6. bilateral class ii molar and canine relationship is at least 3.5 mm, 7. patients who are in mp3 cap period will be taken according to the tanner-whitehouse wrist and wrist x-ray method. exclusion criteria: 1. having received orthodontic treatment before, 2. having severe maxillary stenosis, 3. severe facial asymmetry according to clinical and x-ray analysis, 4. poor oral hygiene, 5. having mental retardation at a level that will affect the patient's cooperation, 7. having a systemic disease that will affect the orthodontic treatment, 8. congenital anomaly or syndrome.
use of beta-agonists in stable severe congestive heart failure

Conditions: Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy; Heart Failure

Summary: the purpose of this study is to determine whether salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.


Eligibility criteria:
inclusion criteria: * ambulatory patients with a diagnosis of ischemic and non-ischemic cardiomyopathy with a measured ef \<35%, class iii as defined by the nyha with icd and who receive optimal pharmacological therapy. exclusion criteria: * heart failure class i, ii, iv * atrial fibrillation * any significant valvular disease * chronic obstructive pulmonary disease who treated with inhaled β2 agonist * significant kidney disease with egfr \<30% * severe uncontrolled electrolyte abnormalities * prior allergic reaction to salbutamol * pregnancy and nursing women

Keywords: heart failure stage 3 beta 2 agonist n-terminal pro-brain natriuretic peptide ejection fraction <35%
cellular markers in treated or untreated non-tuberculous mycobacterial respiratory infection in patients with cystic fibrosis

Conditions: Non-Tuberculous Mycobacterial Pneumonia

Summary: this study evaluates a diagnostic serological test for non-tuberculous mycobacteria (ntm) infection in cystic fibrosis patients by measuring t cell response. it aims to highlight a dynamic response associated to the pathogen's presence. this multicenter case-control study involves two populations, providing a better understanding of the circulating t-ifnγ-mnt response in these patients.

background: evidence shows that non-tuberculous mycobacterial (ntm) infections have increased and are 1,000 to 8,000 times more frequent in patients with cystic fibrosis compared to the general population. the diagnosis is based on clinical, radiological, and microbiological criteria. unfortunately, the first two criteria lack specificity, and microbiological detection of ntm is limited due to frequent sputum contamination by other pathogens in cystic fibrosis patients. given these factors and the high incidence of ntm infections in this population, alternative diagnostic methods are necessary. aim: this study aims to validate an innovative diagnostic test based on the igra (interferon-gamma release assay) method, which measures t lymphocyte response to interferon gamma (ifnγ). the test will be conducted on a subset of patients selected from the ciment cohort (id-rcb: 2017-a00025-48). this cohort consists of cystic fibrosis patients whose ntm infection prevalence has been previously assessed. method: this research is a multicenter case-control study. it includes two groups: a case group of patients with positive serological and/or microbiological responses indicating ntm infection, and a control group of patients without such responses. the test measures the host's immune response by evaluating circulating t cell activity. specifically, it measures ifnγ release when t cells are in contact with ntm antigens. this method provides more informative diagnostics of ntm infection dynamics compared to serology or microbiology, which have known technical limitations. the study involves a single visit, which is part of the routine care for cystic fibrosis patients. during this visit, a routine blood draw will be performed and an additional 7 ml tube will be collected.

Eligibility criteria:
inclusion criteria: * patient ≥18 years * patient previously included in the ciment study * patient with a confirmed diagnosis of cystic fibrosis regardless of cftr genotype * patient affiliated to the social security system * patient registered in the french cystic fibrosis registry * adult patient capable of spontaneous expectoration or after induction exclusion criteria: * lung transplant patients * person placed under judicial protection * pregnant and breastfeeding women

Keywords: cystic fibrosis interferon gamma release assay diagnostic test
rewalk personal device postmarket study

Conditions: Injuries, Spinal Cord

Summary: this study seeks to further evaluate the multi-tiered training program and to further explore the overall safety profile of the rewalk personal device outside of the institutional setting under conditions of routine medical practice.

this study will monitor and further describe the long-term safety of the rewalk personal device for subjects and their companions in institutional and non-institutional environments, such as the clinic, home, and community. the study will also evaluate the adequacy of the multi-tiered training program of the rewalk personal device for subjects, their companions, and their clinical trainers, monitor and further describe all rewalk personal device malfunctions and screen for potential unexpected adverse events.

Eligibility criteria:
inclusion criteria: * for use in institutional and non-institutional environments: subjects with spinal cord injury at levels t7 to l5. * age ≥ 18 years old; * hands and shoulders can support crutches or a walker; * healthy bone density; * skeleton does not suffer from any fractures; * able to stand using a device such as easystand; * in general good health; * height is between 160 cm and 190 cm (5'3" - 6'2"); * weight does not exceed 100 kg (220 lbs); * proficiency in spoken and written english language. exclusion criteria: * history of severe neurological injuries or disease other than sci (ms, cp, als, tbi, etc.); * severe concurrent medical disease, including infections, circulatory, heart or lung, pressure sores; * severe spasticity (ashworth 4) * uncontrolled clonus; * unstable spine or unhealed limbs or pelvic fractures; * heterotopic ossification; * significant contractures; * psychiatric or cognitive situations that may interfere with proper operation of the device or participation in this study; * pregnancy
mobile health strategies for veterans

Conditions: Coronary Heart Disease

Summary: the purpose of this study is to determine whether text messages/messaging (tm) or a mobile application (app), compared with an educational website-control provided to all veterans, can improve adherence to antiplatelet therapy among patients following acute coronary syndrome or percutaneous coronary intervention (acs/pci).

adherence to antiplatelet medications is critical to prevent life threatening complications (i.e., stent thrombosis); yet rates of non-adherence range from 21-57% by 12 months. mobile technology through tm or mobile apps is a practical and inexpensive strategy to promote behavior change and enhance medication adherence. the three specific aims of this proposal are to: 1) determine preferences for content and frequency of tm to promote medication adherence through focus groups; 2) determine the most patient-centered app to promote adherence through a content analysis of all commercially available apps for medication adherence and focus groups centered on usability; and 3) compare adherence to antiplatelet medications in 225 veterans post acs/pci through a randomized controlled trial. participants will be randomized to either tm, mobile app, or website-control group. the focus groups will be stratified by low/high mobile phone use and sex.

Eligibility criteria:
inclusion criteria: * ≥ 21 years of age, * recent acs or pci within 1 week * new antiplatelet (thienopyridine) prescription * owns a smartphone exclusion criteria: * cognitive impairment * lack of english proficiency/literacy

Keywords: mobile health veterans cardiovascular disease medication adherence